文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

美托洛尔治疗梗阻性肥厚型心肌病的随机试验

Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

该双盲安慰剂对照随机交叉试验纳入29例有症状的梗阻性肥厚型心肌病患者,比较美托洛尔与安慰剂对左室流出道梗阻、症状及运动能力的影响。结果显示美托洛尔降低静息和运动时左室流出道压差,改善心功能分级和的生活质量,但最大运动能力无变化。

要点

  • 美托洛尔降低梗阻性HCM患者静息和运动时左室流出道压差。
  • 美托洛尔改善NYHA心功能分级和心绞痛分级及生活质量。
  • 美托洛尔未改善最大运动能力和峰值耗氧量。

核心结论

  • 与安慰剂相比,美托洛尔降低梗阻性HCM患者静息和运动时左室流出道梗阻,缓解症状并改善生活质量,但最大运动能力保持不变。

研究设计与样本

  • 双盲、安慰剂对照、随机交叉试验,2018年5月至2020年9月纳入29例NYHA心功能II级或以上的梗阻性HCM患者。
  • 患者按随机顺序接受美托洛尔或安慰剂,各连续2周。

主要发现

  • 美托洛尔组静息左室流出道压差为25 mm Hg(IQR 15-58),安慰剂组为72 mm Hg(IQR 28-87),P=0.007。
  • 美托洛尔组峰值运动时左室流出道压差为28 mm Hg(IQR 18-40),安慰剂组为62 mm Hg(IQR 31-113),P<0.001。
  • 美托洛尔组运动后左室流出道压差为45 mm Hg(IQR 24-100),安慰剂组为115 mm Hg(IQR 55-171),P<0.0001。
  • 美托洛尔组14%患者NYHA III级或以上,安慰剂组38%,P<0.01;美托洛尔组无患者CCS III级或以上,安慰剂组10%,P<0.01。
  • 美托洛尔组KCCQ-OSS为76.2±16.2,安慰剂组为73.8±19.5,P=0.039;峰值耗氧量和NT-proBNP两组无差异。

临床怎么用

  • 对于有症状的梗阻性HCM患者,美托洛尔可考虑用于降低左室流出道梗阻和改善症状及生活质量。
  • 美托洛尔治疗不以提高最大运动能力为目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of β-adrenergic receptor blocking agents in symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) rests on clinical experience and observational cohort studies. OBJECTIVES: This study aimed to investigate the effects of metoprolol on left ventricular outflow tract (LVOT) obstruction, symptoms, and exercise capacity in patients with obstructive HCM. METHODS: This double-blind, placebo-controlled, randomized crossover trial enrolled 29 patients with obstructive HCM and New York Heart Association (NYHA) functional class II or higher symptoms from May 2018 to September 2020. Patients received metoprolol or placebo for 2 consecutive 2-week periods in random order. The effect parameters were LVOT gradients, NYHA functional class, Canadian Cardiovascular Society (CCS) angina class, Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS), and cardiopulmonary exercise testing. RESULTS: Compared with placebo, the LVOT gradient during metoprolol was lower at rest (25 mm Hg [interquartile range (IQR): 15-58 mm Hg] vs 72 mm Hg [IQR: 28-87 mm Hg]; P = 0.007), at peak exercise (28 mm Hg [IQR: 18-40 mm Hg] vs 62 mm Hg [IQR: 31-113 mm Hg]; P < 0.001), and postexercise (45 mm Hg [IQR: 24-100 mm Hg] vs 115 mm Hg [IQR: 55-171 mm Hg]; P < 0.0001). During metoprolol treatment, 14% of patients were in NYHA functional class III or higher compared with 38% of patients receiving placebo (P < 0.01). Similarly, no patients were in CCS class III or higher during metoprolol treatment compared with 10% during placebo treatment (P < 0.01). These findings were confirmed by higher KCCQ-OSS during metoprolol treatment (76.2 ± 16.2 vs 73.8 ± 19.5; P = 0.039). Measures of exercise capacity, peak oxygen consumption, and N-terminal pro-B-type natriuretic peptide did not differ between the study arms. CONCLUSIONS: Compared with placebo, metoprolol reduced LVOT obstruction at rest and during exercise, provided symptom relief, and improved quality of life in patients with obstructive HCM. Maximum exercise capacity remained unchanged. (The Effect of Metoprolol in Patients with Hypertrophic Obstructive Cardiomyopathy [TEMPO]; NCT03532802).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Dybro AM, Rasmussen TB, Nielsen RR, et al. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021. PMID: 34915981. doi:10.1016/j.jacc.2021.07.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。